公开(公告)号：US20240269064A1

公开(公告)日：2024-08-15

申请号：US18627994

申请日：2024-04-05

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Jennifer Eng-Wong ,  Whitney Kirschbrown ,  Tarik Ali Khan ,  Jasper Lin ,  Sreedhara Alavattam ,  Amit Garg ,  Sarah Heeson ,  Tanja Badovinac-Crnjevic ,  Christine Wurth

IPC: A61K9/00 ,  A61K9/08 ,  A61K38/47 ,  A61K39/00 ,  A61K39/395 ,  A61K47/18 ,  A61K47/20 ,  A61K47/26 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32

CPC classification number: A61K9/0019 ,  A61K9/08 ,  A61K38/47 ,  A61K39/001106 ,  A61K39/39591 ,  A61K47/183 ,  A61K47/20 ,  A61K47/26 ,  A61P35/00 ,  C07K16/32 ,  C12Y302/01035 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/585 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/90

Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.

公开(公告)号：US20230048743A1

公开(公告)日：2023-02-16

申请号：US17811316

申请日：2022-07-08

Applicant: Genentech Inc.

Inventor： Elizabeth Sara Hecht ,  Shrenik Chetan Mehta ,  Wendy Noel Sandoval ,  Sreedhara Alavattam ,  Nathaniel Robert Tzizik-Swanson

IPC: C07K16/40 ,  C12N15/85

Abstract: The present application relates to recombinant antibodies that are engineered to alter interactions between the antibodies and one or more endogenous lipases of a host cell used to produce the antibodies. In some cases, the antibodies are mutated in the heavy chain constant region, such as at CH1, CH2, and/or CH3. In other cases, the antibodies are mutated to alter their glycosylation profile.